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Abstract
Objectives: Over the past 2 decades, significant
advances have been made in the management of
infections after transplant; however, transplant
recipients are still at high risk of infectious com -
plications. This study aimed to evaluate the prevalence
of bacterial infections and antimicrobial resistance
patterns in kidney transplant recipients.
Materials and Methods: This cross-sectional study
included 356 patients who received kidney trans plants,
regardless of the underlying disease, from 2013 to 2015
at the Montaserieh Transplant Hospital (Mashhad, Iran).
Clinical samples collected from patients were sent to the
microbiology laboratory for culture processing. Typing
of bacteria was conducted, and susceptibility testing
was performed according to the Clinical and Laboratory
Standards Institute guideline by use the of disk
diffusion agar method. Data were then analyzed 
by SPSS software (SPSS: An IBM Company, IBM
Corporation, Armonk, NY, USA) using chi-square test.
Results:Among 356 kidney recipients (206 men and 150
women), 115 (32.3%) received transplants from living
donors and 241 (67.7%) received transplants from
deceased donors. Of 356 total patients, 112 patients
(31.5%) had an infection at various times after
transplant. The most common gram-negative and
gram-positive isolated bacteria were Escherichia coli
and coagulase-negative Staphylococcus, with
prevalence rates of 66.1% and 48.6%. Most of the
isolates were resistant against selected antibiotics.
Conclusions: Because of the high prevalence of
infection among transplant patients, infection
prevention should receive more attention, and
antibiotic susceptibility should be determined before
treatment.
Key words: Antibiotic resistance, Coagulase-negative
Staphylococcus, Escherichia coli, Renal transplantation 
Introduction
One of the primary and major aims in organ
transplant is the effective prevention and treatment
of infections. During the previous 2 decades,
significant advances have been made in the
management of infection after transplant. However,
transplant recipients are still at high risk of infectious
complications, due to the surgical interventions,
immunosuppressive therapy, and exposure to the
environment.1 In transplant patients, there are
generally 3 times the incidences of infections after
transplant, which are usually divided as those that
occur during the first month posttransplant, those
that occur 2 to 6 months posttransplant, and those
that occur more than 6 months posttransplant.
Most infections in the first month, especially the
first 2 weeks after transplant, occur in relation to
technical and operative factors. These infections
include pneumonia, wound infection, those related
to intravenous catheter, and urinary tract infection.2
In addition are complications that result from
infections causing the death of organ transplant
recipients and in some cases organ transplant
rejections, especially infections that are caused by
drug-resistant bacteria.2-4 Urinary tract infections are
the most common problem after kidney transplant.
Almost 70% of these infections are caused by gram-
negative bacteria, especially Escherichia coli and
Klebsiella pneumoniae.4 In addition to gram-negative
bacteria, some gram-positive bacteria, including
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Staphylococcus and Enterococcus species, are known to
cause infection in these patients.5 The primary
concern in the treatment of these infections is
resistance of bacteria to antimicrobial agents through
different mechanisms. For example, resistance in
gram-negative bacteria mostly occurs through
extended-spectrum beta-lactamases (ESBLs) and
carbapenemase enzymes.4,6 In gram-positive
bacteria, resistance occurs through penicillinase7 and
genes that cause resistance to vancomycin.7,8
Therefore, the aim of this study was to evaluate the
prevalence of bacterial infections, their types, and the
antibiotic resistance rate in kidney recipients.
Materials and Methods
This cross-sectional study included 356 patients who
received kidney transplants at the Montaserieh
Transplant Hospital (Mashhad, Iran), regardless of
the underlying diseases, from March 20, 2013 to
March 20, 2015. Clinical samples collected from
patients were sent to the microbiology laboratory for
culture processing. Samples were cultured on
suitable media (blood agar, MacConkey agar, and so
forth) and incubated overnight. Detection and
identification of isolates were done using micro -
biology and chemical tests such as oxidase, catalase,
and growth on tryptic soy agar, SIM (sulfide-indole-
motility), LIA agar, urea, and Simon citrate media.
The typing of gram-negative and gram-positive
bacteria was carried out, and susceptibility testing
was performed according to the Clinical and
Laboratory Standards Institute guideline by use of
disk diffusion agar method. In brief, a bacterial
suspension with concentration of 0.5 MF (MacFarland
standard 1.5 × 108 cfu/mL) was prepared in brain-
heart broth medium. The bacterial suspension was
spread densely with sterile swab on Mueller-Hinton
agar medium.
Antibiotic disks used in this study included
gentamycin, amikacin, nitrofurantoin, ciprofloxacin,
imipenem, chloramphenicol, meropenem, cephalexin,
amoxicillin, norfloxacin, nalidixic acid, cotrimoxazole,
ceftriaxone, tetracycline, ofloxacin, ceftazidime,
ceftizoxime, cefixime, vancomycin, ampicillin,
erythromycin, and clindamycin (High Media
Company, India). Obtained results were analyzed by
SPSS software (SPSS: An IBM Company, IBM
Corporation, Armonk, NY, USA) using chi-square
test.
Results
Of 356 patients who received kidney transplants (206
male and 150 female), 115 (32.3%) received
transplants from living donors and 241 (67.7%)
received transplants from brain-dead donors. Of 356
patients, 112 (31.5%; 67 females and 45 males) had
positive cultures at various times after transplant. In
total, 164 isolates were detected, of which 29 isolates
(17.7%) were from patients who received kidneys
from living donors and 135 isolates (82.3%) were
from patients who received kidneys from brain-dead
donors (in 22 patients, more than 1 or 2 different
isolates were detected; also, 30 patients had positive
cultures over 2 or 3 periods after transplant).
Infection rates were 21% during the first month after
transplant, 13.3% between 2 and 6 months after
transplant, and 5.6% at 6 months after transplant.
The 164 isolates (127 cases of gram-negative and 37
cases of gram-positive) were isolated from different
sources (128 samples were from urine, 17 samples
from blood, and 10 samples from discharge).
The most common gram-negative and gram-
positive bacteria causing infections were Escherichia
coli and coagulase-negative Staphylococcus, with
prevalence rates of 66.1% and 48.6% (Table 1). Based
on antibiotic susceptibility testing, the highest and
lowest rates of antibiotic resistance among gram-
positive bacteria were against nalidixic acid (100%)
and nitrofurantoin (35.1%), respectively (Table 2).
The highest and lowest rates of antibiotic resistance
among gram-negative bacteria were against
amoxicillin (93.4%) and meropenem (19.6%),
respectively (Table 3). Unfortunately, 19 isolates (11
isolates of gram-negative and 8 isolates of gram-
positive bacteria) were resistant to all antibiotics. The
11 gram-negative-resistant isolates included 4
Klebsiella pneumoniae, 4 Escherichia coli, and 3
Acinetobacter isolates. The 8 gram-positive-resistant
isolates included 5 coagulase-negative Staphylococci,
2 Enterococcus species, and 1 Streptococcus species.
Davood Mansury et al/Experimental and Clinical Transplantation (2017)
table 1. Prevalence of Gram-Negative/Positive Isolates in Patients With Positive
Culture
Gram Negative Gram Positive
Type of Bacteria Number Type of Bacteria Number
Escherichia coli 84 Coagulase-negative Staphylococci 18
Klebsiella species 32 Streptococcus  species 8
Acinetobacter species 6 Enterococcus species 6
Enterobacter species 2 Staphylococcus aureus 5
Proteus species 2
Pseudomonas species 1
Total 127 Total 32
Davood Mansury et al/Experimental and Clinical Transplantation (2017)
Discussion
Urinary tract infection is the most common bacterial
infection in kidney transplant recipients, and
Escherichia coli is the most common bacteria that can
be isolated from these infections. One of the risk
factors for urinary tract infection is receiving a
kidney from a donor after brain death.9 Of 164
isolates, we had 135 cases isolated from patients who
received transplants from donors after brain death,
which was statistically significant (P = .01). It is
noted, however, that 67.7% of transplants were from
people who had brain death. Another risk factor for
infection is related to female sex. In our study, of 112
patients who had a positive culture, 67 patients
(59.8%) were females; it should be noted that, in our
cohort of 356 transplant patients, 150 were women
(42.1%) and 206 were men (56.4%). Furthermore, of
the 67 positive cultures in female patients, 53
received kidneys from patients after brain death and
14 received kidneys from living donors. Of the 45
positive cultures in male patients, 37 received their
grafts from donors after brain death and 8 received
grafts from living donors. Other risk factors included
the use of catheters and prolonged shunts and
increased suppression of the immune system.9
table 2. Results of Susceptibility Testing for Gram-Positive Isolates
Antibiotic Coagulase- Streptococcus Enterococcus Staphylococcus
negative species (8), % species (6), % aureus (5), %
Staphylococci 
(18), %
Vancomycin
S 22.2 87.5 66.6 100
R 77.8 12.5 33.3 0
Gentamycin
S 16.7 25 16.6 60
R 83.3 75 83.4 40
Amikacin
S 0 37.5 16.6 -
R 100 62.5 83.4 -
Nitrofurantoin
S 72 37.5 50 100
R 28 62.5 50 0
Ciprofloxacin
S 22.2 12.5 0 -
R 77.8 87.5 100 -
Chloramphenicol
S 50 25 - -
R 50 75 - -
Cephalexin
S 11 12.5 0 0
R 89 87.5 100 100
Ampicillin
S 28 12.5 50 20
R 72 87.5 50 80
Norfloxacin
S 28 0 0 -
R 72 100 100 -
Nalidixic acid
S 0 0 0 -
R 100 100 100 -
Co-trimoxazole
S 22.2 25 0 40
R 77.8 75 100 60
Ceftriaxone
S 28 0 0 0
R 72 100 100 100
Tetracycline
S 11 0 - -
R 89 100 - -
Erythromycin
S 16.7 - - 40
R 83.3 - - 60
Clindamycin
S 28 - - 60
R 72 - - 40
Abbreviations: R, resistance; S, susceptibility
table 3. Results of Susceptibility Testing for Gram-Negative Isolates
Antibiotic Escherichia Klebsiella Acinetobacter
coli (84), % species (32), % species (6), %
Gentamycin
S 38 43.7 16.6
R 62 56.3 83.3
Amikacin
S 58.3 50 50
R 41.7 50 50
Nitrofurantoin
S 53.5 34.4 0
R 46.5 65.6 100
Ciprofloxacin
S 31 28.1 16.7
R 69 71.9 83.3
Imipenem
S 66.6 59.4 33.3
R 33.3 40.6 66.6
Chloramphenicol
S 50 84.4 -
R 50 15.6 -
Meropenem
S 83.3 75 66.6
R 16.6 25 33.3
Cephalexin
S 8.3 9.4 -
R 91.6 91.6 -
Amoxicillin
S 8.3 3.1 0
R 91.6 96.9 100
Norfloxacin
S 28.5 28.1 -
R 71.5 71.9 -
Nalidixic acid
S 22.6 18.7 -
R 77.4 81.3 -
Co-trimoxazole
S 12 9.4 0
R 88 90.6 100
Ceftriaxone
S 12 9.4 16.7
R 88 90.6 83.3
Tetracycline
S 7.1 12.5 -
R 92.9 87.5 -
Ofloxacin
S 33.3 43.7 -
R 66.6 56.3 -
Ceftazidime
S 17.8 12.5 0
R 82.2 87.5 100
Ceftizoxime
S 25 18.7 -
R 75 81.3 -
Cefixime
S 8.3 0 -
R 91.7 100 -
Abbreviations: R, resistance; S, susceptibility
One way to prevent infections after transplant is
prophylaxis with antibiotics such as co-trimoxazole.
In those who have allergies to these antibiotics,
prophylaxis with nitrofurantoin is recommended.10
In our study, the rate of resistance to co-trimoxazole
was between 88% and 100% among the most
common gram-negative bacteria causing urinary
tract infections, which showed the highest resistance
to these antibiotics. Use of antibiotics such as third-
generation cephalosporins for prophylaxis can lead
to bacterial resistance and can result in ESBLs in
kidney transplant recipients.
Due to the overuse of these antibiotics, the
resistance rate has increased; therefore, the drug
choices for treatment of these infections are limited.4
Extended-spectrum beta-lactamases are a class of
beta-lactamase enzymes; its diagnosis is particularly
important in the treatment of infections and
prevalence of antibiotic resistance.11 These enzymes
cause complete hydrolysis of oxyimino beta-lactams,
which are present in structures of third-generation
cephalosporins.12 The production of ESBLs in
bacteria not only reduce the effectiveness of
treatment with beta-lactams, especially broad-
spectrum cephalosporins and monobactams, but also
can lead to development of multiple resistance to
other antimicrobial agents such as aminoglycosides
and fluoroquinolones, which are widely used for
treatment of infections caused by bacteria.13
Extended spectrum beta-lactamases produced
mostly by Klebsiella pneumoniae and E. coli, in other
Enterobacteriaceae species, and in other nonfermented
gram-negative bacteria like Acinetobacter baumannii
and Pseudomonas aeruginosa have also been
identified.14
In our study, resistance to third-generation
cephalosporins was between 75% and 100%,
indicating resistance of these gram-negative bacteria
to these antibiotics. The highest resistance was
against cefixime (91.7% to 100%), and the lowest
resistance was against ceftizoxime (75%). It should
be noted that, because resistance to broad-spectrum
cephalosporins occur by different mechanisms and
beta-lactamase enzymes are one of them, diagnosis
for this type of resistance is done using combination
disks with beta-lactamase inhibitors such as
clavulanic acid, tazobactam, and sulbactam,15 where
the common antibiogram methods are used in most
microbiology laboratories. In our study, because of
not using combined cephalosporins disks for all
isolates to detect the ESBLs, it was impossible to
determine the exact amount of resistance. Regarding
the high level of resistance of gram-negative isolates
to these antibiotics, it was expected that the
prevalence of isolates producing these enzymes
would be high.
For 7 isolates, resistance has been reported. In a
study conducted in 2010, which included the period
from 2007 to 2010, resistance increased 14%, mainly
because of increased prevalence of organisms
producing ESBLs.16 This has increased concerns to
select an effective antibiotic for treatment.
Carbapenems (such as imipenem and meropenem)
and β-lactam antibiotics are widely used to treat
infections as one of the last lines of therapy.
Carbapenem resistance is a major threat in treatment
of nosocomial infections, which have several
mechanisms, such as changes in the purines,
expression of efflux pumps, and beta-lactamases
hydrolyzing the carbapenems (carbapenemase).17-19
Prevalence of carbapenem-resistant gram-negative
bacteria between transplant recipients can cause
increased mortality in these patients.
In our study, resistance to imipenem was
significantly more than meropenem (the resistance
rate to imipenem in Klebsiella and E. coli was 40.6%
and 33.3%, respectively, with 25% and 16.6% for
meropenem, respectively). In study by Lanini and
associates, resistance rate to carbapenems was 26.5%
among organ recipients. The most resistance was
caused by Klebsiella isolates, which is consistent with
our study. It is worth noting that the resistance rate in
isolates of Klebsiella species has been shown to be
49.1%; the difference may be because most of the
isolates were isolated among recipients of hearts and
lungs.6
In addition to gram-negative bacteria resistance
to cephalosporins and carbapenems, controlling
gram-positive strains resistant to the spread of beta-
lactam antibiotics (which are resistant to penicillinase,
such as oxacillin and glycopeptide-like vancomycin),
including methicillin-resistant Staphylococcus aureus
(MRSA) and vancomycin-resistant Enterococci (VRE)
isolates, are of special importance. In addition to
development of resistance to these antibiotics,
colonization in patients before and after transplant
plays a major role in incidence of infection after
transplant. In a meta-analysis conducted in 2014 by
Ziakas and colleagues,5 the MRSA colonization rate
in patients was 8.5% and colonization rates of VRE
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in transplant patients before and after surgery were
11.9% and 16.2%. This showed that infection after
transplant in these patients was approximately 6 to
10 times higher than in other patients. Therefore, it is
necessary for patients to be checked for these
resistant isolates before transplant and for necessary
actions to be taken to remove them.5 In the present
study, of 5 Staphylococcus aureus isolates, 2 cases were
identified as MRSA; of 6 Enterococcus isolates, 2 cases
were identified as VRE.
Conclusions
Regarding the high prevalence of infection in kidney
recipients, first, control of infection should be
performed during patient hospitalization. Second,
the most effective antibiotics for prophylaxis must be
selected. Third, new methods of susceptibility testing
by phenotypic and possible genotypic methods
should be used. Furthermore, to prevent transmission
of MRSA from carriers to these susceptible patients,
transplant center personnel should be evaluated for
carriage of these bacteria.
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